Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 10/20 | 0.44 |
| ▸ | PRF1 | P14222 | 3/20 | 0.42 |
| ▸ | POLQ | O75417 | 1/20 | 0.41 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14737012 | 0.89 | PRF1 (0.46) | PDE4DPRF1POLQABCG2IMPDH2 | |
| SCHEMBL2591566 | 0.89 | PDE4D (0.48) | PDE4DPRF1POLQCYP3A4MAOA | |
| SCHEMBL17599585 | 0.89 | PDE4D (0.48) | PDE4DPRF1POLQABCG2CYP3A4 | |
| SCHEMBL2586145 | 0.88 | PDE4D (0.46) | PDE4DPRF1POLQCYP3A4MAOA | |
| SCHEMBL2584420 | 0.87 | PDE4D (0.48) | PDE4DPRF1POLQCYP3A4MAOA | |
| SCHEMBL7712984 | 0.87 | ABCG2 (0.42) | PDE4DPRF1POLQABCG2IMPDH2 | |
| SCHEMBL2588276 | 0.87 | PDE4D (0.45) | PDE4DPRF1POLQCYP3A4MAOA | |
| SCHEMBL2591371 | 0.86 | PDE4D (0.43) | PDE4DPRF1POLQABCG2IMPDH2 | |
| SCHEMBL2588167 | 0.86 | PDE4D (0.44) | PDE4DPRF1POLQCYP3A4MAOA | |
| SCHEMBL2588346 | 0.85 | PRF1 (0.44) | PDE4DPRF1POLQABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2563770-B1 | BIARYL PHOSPHODIESTERASE INHIBITORS | LEO PHARMA AS (DK) | 2016-03-23 | — | — | EP | disclosed |
| US-9051290-B2 | Biaryl phosphodiesterase inhibitors | LEO PHARMA A/S (DK) | 2015-06-09 | — | — | US | disclosed |
| US-20130059853-A1 | BIARYL PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2013-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059853-A1 | BIARYL PHOSPHODIESTERASE INHIBITORS | PDE3B, PDE3A, PDE4A | PDE4D 10/4885PRF1 3550/4885POLQ 1717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.